PT  - JOURNAL ARTICLE
AU  - Kristensen, Kathleen
AU  - Boodram, Basmattee
AU  - Avila, Wendy
AU  - Pineros, Juliet
AU  - Latkin, Carl
AU  - Mackesy-Amiti, Mary-Ellen
TI  - Perceptions of access to harm reduction services during the COVID-19 pandemic among people who inject drugs in Chicago
AID  - 10.1101/2023.10.10.23296820
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.10.23296820
4099  - http://medrxiv.org/content/early/2023/10/10/2023.10.10.23296820.short
4100  - http://medrxiv.org/content/early/2023/10/10/2023.10.10.23296820.full
AB  - Background The COVID-19 pandemic amplified the risk environment for people who inject drugs (PWID), making continued access to harm reduction services imperative. Research has shown that some harm reduction service providers were able to continue to provide services throughout the pandemic. Most of these studies, however, focused on staff perspectives, not those of PWID. Our study examines changes in perceptions of access to harm reduction services among PWID participating in a longitudinal study conducted through the University of Illinois-Chicago’s Community Outreach Intervention Project field sites during the COVID-19 pandemic.Methods Responses to a COVID-19 module added to the parent study survey that assessed the impact of COVID-19 on PWID participating in an ongoing longitudinal study were analyzed to understand how study participants’ self-reported access to harm reduction services changed throughout the pandemic. Mixed effects logistic regression was used to examine difficulty in syringe access as an outcome of COVID-19 phase.Results Most participants reported that access to syringes and naloxone remained the same as prior to the pandemic. Participants had significantly higher odds of reporting difficulty in accessing syringes earlier in the pandemic.Conclusions The lack of perceived changes in harm reduction access by PWID and the decrease in those reporting difficulty accessing syringes as the pandemic progressed suggests the efficacy of adaptations to harm reduction service provision (e.g., window and mobile service) during the pandemic. Further research is needed to understand how the COVID-19 pandemic may have impacted PWIDs’ engagement with harm reduction services.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data analyzed in this manuscript are part of a study that was approved by the Institutional Review Board at the University of Illinois Chicago (Protocol #2017-0388). Informed, written consent was obtained from all study participants prior to participation following the guidelines set out by the IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.